Companies · Biotech / Pharma

Tychon Biosciences LLC

MINNEAPOLIS · Biotech / Pharma · refined from filed group “Other Technology

Diligence memoA one-page analyst read on Tychon Biosciences LLC — recommendation, valuation, rhythm, risks.
$671K
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 75%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Tychon Biosciences LLC looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.57× the median modeled value of Pre-Seed Biotech / Pharma companies in 2016–2018 (12 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.7 yr ago; this sector typically re-raises about every 15 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Tychon Biosciences LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
10.7 yr record
Peak capital year was 2015 with $471K across 1 filings.
Market position
ahead of 26% of Biotech / Pharma peers
Capital scale is ahead of 26% of Biotech / Pharma peers; modeled value is above 34% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2015: $471K across 1 filings.
  • Largest single filing was $471K on 2015-11-02.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Tychon Biosciences LLC is one of 227 Biotech / Pharma companies tracked from MINNEAPOLIS. By capital raised it ranks in the long tail (ahead of 26% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2014
Year incorporated
2018-10-09
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2015-11-02 Raised $471K (real) Modeled valuation $24M (est)$471K$24MPre-Seed2015Pre-Seed · 2018-10-09 Raised $200K (real) Modeled valuation $10M (est)$200K$10MPre-Seed2018+$200KCumulative $671K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$471K · 2015
Pre-Seed extension$200K · 2018

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$10.2M
Base estimate est.
$109K
Conservative case
$116.0M
Upside case
$1.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $24.1M · 2015-11-022015Pre-Seed · modeled $10.2M · 2018-10-092018
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 45% high
1.83×/yr
Annual markup
2.48×/yr upside case
6.0 yr
Elapsed time used
7.7 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
35 mo
Avg between rounds
$229K/yr
Capital velocity
10.7 yr
On record since
2015
First round
2
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$671K
Sector median$5.6M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.6× of median
This company$200K
Sector median$317K
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$10.2M
Sector median$30.5M

Raised more than 26% of sector peers (real $). Modeled value above 34% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #7 of 12.

This companyCohort peer
$1.0M$10.0M$100.0M$10K$100K$1.0M$10.0MCapital raised (log)Orbis Biosciences, Inc · Pre-Seed Raised $1.2M · modeled $50.4M (est)Nexion Biosciences Inc · Pre-Seed Raised $814K · modeled $41.6M (est)Synereca Pharmaceuticals, Inc. · Pre-Seed Raised $900K · modeled $30.7M (est)Novome Biotechnologies, Inc. · Pre-Seed Raised $536K · modeled $27.4M (est)Me Biosciences, Inc. · Pre-Seed Raised $1.4M · modeled $25.6M (est)Continuum Biosciences, Inc. · Pre-Seed Raised $500K · modeled $25.6M (est)Empire Biotechnologies, Inc. · Pre-Seed Raised $110K · modeled $5.6M (est)Olive Pharmacy, LLC · Pre-Seed Raised $100K · modeled $5.1M (est)Therapeutic Solutions International, Inc. · Pre-Seed Raised $200K · modeled $5.1M (est)Gesea Biosciences, Inc. · Pre-Seed Raised $100K · modeled $5.1M (est)Pharmacy Specialty Group, LLC · Pre-Seed Raised $100K · modeled $5.1M (est)Tychon Biosciences LLC (this company) Raised $671K · modeled $10.2M (est)Tychon Biosciences LLC
CompanyStageRaised · realValue · estvs peer med.
Orbis Biosciences, IncPre-Seed$1.2M$50.4M2.81×
Nexion Biosciences IncPre-Seed$814K$41.6M2.32×
Synereca Pharmaceuticals, Inc.Pre-Seed$900K$30.7M1.71×
Novome Biotechnologies, Inc.Pre-Seed$536K$27.4M1.53×
Me Biosciences, Inc.Pre-Seed$1.4M$25.6M1.43×
Continuum Biosciences, Inc.Pre-Seed$500K$25.6M1.43×
Tychon Biosciences LLC this companyPre-Seed$671K$10.2M0.57×
Empire Biotechnologies, Inc.Pre-Seed$110K$5.6M0.31×
Olive Pharmacy, LLCPre-Seed$100K$5.1M0.29×
Therapeutic Solutions International, Inc.Pre-Seed$200K$5.1M0.29×
Gesea Biosciences, Inc.Pre-Seed$100K$5.1M0.29×
Pharmacy Specialty Group, LLCPre-Seed$100K$5.1M0.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$471K2015-11-02$2.6M$24.1M85%
Pre-Seed$200K2018-10-09$1.1M$10.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$471K2015-11-02
    • First recorded raise — entered as Pre-Seed.
    • 7 investors on this round.
  2. Pre-Seed$200K2018-10-09
    • Raised again after 35 mo — slower than the ~15 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 2 investors on this round.
Intelligence
2021 ~Q3
Modeled next raise · ~35mo cadence
$200K
Modeled next size est.range $200K$320K
0.4×
Last step-up
$229K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Danny J. Cunagin9 other2015-11
Troy D. Kopischke9 other2015-11
Arek Z. Dudek, MD PhD2018-10
Charles J. Muscoplat, PhD2018-10
John Z. MacDonald, PhD2018-10
Mark D. Sylvester2015-11
Mark Z. Sylvester2018-10
Registry & provenance

Tychon Biosciences LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1659363
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Exosite LLCOther TechnologyPre-Seed$675K$15.9Mnetwork2 shared operators · same stage
Steady State Imaging LLCOther Health CarePre-Seed$550K$7.7Mnetwork2 shared operators · same stage
Invenshure Fund II, LPOther TechnologyPre-Seed$456K$19.3Mnetwork2 shared operators · same stage
Stratum Biosciences Inc.Biotech / PharmaPre-Seed$650K$1.1Msame sector · same stage
Solaris Vaccines, Inc.Biotech / PharmaPre-Seed$610K$1.0Msame sector · same stage
Platinum Biosciences, Inc.Biotech / PharmaPre-Seed$750K$25.6Msame sector · same stage
EOF Bio LLCBiotech / PharmaPre-Seed$584K$4.9Msame sector · same stage
Nexion Biosciences IncBiotech / PharmaPre-Seed$814K$41.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
rMark Bio, Inc.Biotech / PharmaSeed$114.1M85%
Onyx Bio, Inc.Biotech / PharmaSeries A$19.6M83%
Barnwell Bio, Inc.Biotech / PharmaSeries A$22.3M83%
Biopharmaceutical Research CoOther TechnologySeries B$6.9M83%
Capra Biosciences, Inc.Biotech / PharmaSeed$2.1M82%
Penrhos Bio LtdBiotech / PharmaPre-Seed$2.4M82%
Iota Biosciences, Inc.Biotech / PharmaSeries B$551.7M82%
Sudo Biosciences, Inc.Biotech / PharmaSeries C$685.8M82%
Frequently asked
How much funding has Tychon Biosciences LLC raised?
Tychon Biosciences LLC has raised approximately $671K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Tychon Biosciences LLC's estimated valuation?
Provath's modeled valuation for Tychon Biosciences LLC is approximately $10.2M (modeled range $109K–$116.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Tychon Biosciences LLC at?
Tychon Biosciences LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Oct 09.
What does Tychon Biosciences LLC do and where is it based?
Tychon Biosciences LLC operates in the Biotech / Pharma sector, based in MINNEAPOLIS.
Explore related

See where Tychon Biosciences LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Tychon Biosciences LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.